Lawrence Vu, MD
Family Medicine · Tukwila, WANPI 1225040801
Payments from drug & device makers
Across 131 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$441
- Gilead$267
- Johnson & Johnson$228
- AbbVie$193
- Boehringer Ingelheim$181
- Lilly USA, LLC$179
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,911100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $441 |
| Gilead | 13 | $267 |
| Johnson & Johnson | 6 | $228 |
| AbbVie(2 entities) | 8 | $193 |
| Boehringer Ingelheim | 5 | $181 |
| Lilly USA, LLC | 7 | $179 |
| Phathom Pharmaceuticals, Inc. | 3 | $161 |
| Bayer | 5 | $133 |
| Merck | 5 | $119 |
| AstraZeneca | 5 | $118 |
| Kowa Pharmaceuticals America, Inc. | 5 | $115 |
| Sanofi Pasteur Inc. | 5 | $113 |
| Dexcom, Inc. | 3 | $98 |
| Pfizer | 5 | $97 |
| Amgen | 4 | $95 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $74 |
| Sanofi-aventis U.S. LLC | 3 | $73 |
| Exact Sciences | 2 | $61 |
| GSK | 2 | $34 |
| Meridian Bioscience Inc. | 2 | $29 |
| VBI Vaccine (delaware) Inc. | 1 | $25 |
| Viiv Healthcare Company | 1 | $25 |
| Novartis | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Krystal Biotech Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$125
How this compares
$2,911 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 125 | $191,458 |
| ProliaDenosumab | 61 | $107,249 |
| VemlidyTenofovir Alafenamide | 62 | $100,742 |
| JanuviaSitagliptin Phosphate | 54 | $77,367 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $26,695 |
| KerendiaFinerenone | 21 | $25,825 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $25,744 |
| XareltoRivaroxaban | 25 | $21,034 |
| EliquisApixaban | 15 | $17,836 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $14,068 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $9,504 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $6,598 |
| LinzessLinaclotide | 12 | $6,021 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 110 | $3,459 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $441 | $191,458125 claims |
| AmgenProlia | $95 | $107,24961 claims |
| GileadVemlidy | $267 | $100,74262 claims |
| MerckJanuvia | $119 | $77,36754 claims |
| BayerKerendia | $133 | $25,82521 claims |
| Johnson & JohnsonXarelto | $228 | $21,03425 claims |
| PfizerEliquis | $97 | $17,83615 claims |
| AstraZenecaSymbicort | $118 | $9,50433 claims |
| AbbVieLinzess | $193 | $6,02112 claims |
| GSKArnuity Ellipta | $34 | $3,11911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Tukwila
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
- Steven SmithAuburn$438K
- John RobinsonEdmonds$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.